Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.

Published in: HIV medicine (2022)

We observed no negative impacts and potential moderate improvements with DTG, providing further support for the rollout of DTG.

Keyphrases